Famotidine Outpatient COVID-19 Treatment Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04389567 |
Recruitment Status :
Completed
First Posted : May 15, 2020
Last Update Posted : June 4, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
A retrospective case series of patients who self-medicated with Famotidine during coronavirus disease 2019 (COVID-19). The study will collect de-identified patient reported outcome measures of patients with confirmed COVID-19 who self-medicated with Famotidine at any dose during the period of illness. Data will be collected by questionnaire and telephone interview.
Inclusion criteria:
Age>18; Ability to give written informed consent for study participation; Confirmed diagnosis of COVID-19; Use of Famotidine at any dose during period of COVID-19 illness
Condition or disease | Intervention/treatment |
---|---|
COVID-19 | Drug: Famotidine |
Study Type : | Observational |
Actual Enrollment : | 10 participants |
Observational Model: | Case-Only |
Time Perspective: | Retrospective |
Official Title: | Famotidine Use in Non-hospitalized Patients With COVID-19: A Case Series |
Actual Study Start Date : | May 12, 2020 |
Actual Primary Completion Date : | May 25, 2020 |
Actual Study Completion Date : | May 25, 2020 |

Group/Cohort | Intervention/treatment |
---|---|
Patients with COVID-19 taking Famotidine
Use of any dose of oral Famotidine during period of COVID-19
|
Drug: Famotidine
Use of oral Famotidine. |
- Symptomatic improvement [ Time Frame: 2 weeks ]Symptoms assessed by severity scores on an ordinal scale; 1=not affected to 4= severely affected
- Peripheral blood oxygen saturation [ Time Frame: 2 weeks ]Oxygen saturation determined by pulse oximetry

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Age >18 years; Ability to give written informed consent; Confirmed COVID-19 diagnosis; Famotidine use during COVID-19 illness
Exclusion Criteria:
none

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04389567
United States, New York | |
Cold Spring Harbor Laboratory | |
Cold Spring Harbor, New York, United States, 11724 |
Principal Investigator: | David A Tuveson, MD PhD | Cold Spring Harbor Laboratory |
Responsible Party: | Northwell Health |
ClinicalTrials.gov Identifier: | NCT04389567 |
Other Study ID Numbers: |
1605914-1 |
First Posted: | May 15, 2020 Key Record Dates |
Last Update Posted: | June 4, 2020 |
Last Verified: | June 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Individual participant data (IPD) will not be shared with other researchers. De-identified data will be reported in a case series publication. All participants have consented to having de-identified data included in a case series report. |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Famotidine |
COVID-19 Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases |
Respiratory Tract Diseases Famotidine Anti-Ulcer Agents Gastrointestinal Agents Histamine H2 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |